METHYLPREDNISOLONE Tablet [Major Pharmaceuticals]

Fluid and Electrolyte Disturbances

Sodium retention

Congestive heart failure in susceptible patients

Hypertension

Fluid retention

Potassium loss

Hypokalemic alkalosis

Musculoskeletal

Muscle weakness

Loss of muscle mass

Vertebral compression fractures

Pathologic fracture of long bones

Tendon rupture, particularly of the Achilles tendon

Steroid myopathy

Osteoporosis

Aseptic necrosis of femoral and humeral heads

Gastrointestinal

Peptic ulcer with possible perforation and hemorrhage

Ulcerative esophagitis

Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

Pancreatitis

Abdominal distention

Dermatologic

Impaired wound healing

Petechiae and ecchymoses

May suppress reactions to skin tests

Thin fragile skin

Facial erythema

Increased sweating

Neurological

Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment

Convulsions

Vertigo

Headache

Endocrine

Development of Cushingoid state

Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness

Menstrual irregularities

Decreased carbohydrate tolerance

Increased requirements of insulin or oral hypoglycemic agents in diabetics

Suppression of growth in children

Manifestations of latent diabetes mellitus

Ophthalmic

Posterior subcapsular cataracts

Glaucoma

Increased intraocular pressure

Exophthalmos

Metabolic

Negative nitrogen balance due to protein catabolism

The following additional reactions have been reported following oral as well as parenteral therapy:

Urticaria and other allergic, anaphylactic or hypersensitivity reactions.

Close

Let's block ads! (Why?)

METHYLPREDNISOLONE Tablet [Major Pharmaceuticals]